Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 15, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price (GBP) | Volume | Transaction Type |
|---|---|---|---|---|
| April 12, 2019 | Ordinary Shares (25p each) | 15.6873 | 29 | Acquisition via Dividend Re-investment (ISA) |
| April 12, 2019 | Ordinary Shares (25p each) | 15.6873 | 25 | Acquisition via Dividend Re-investment (ISA) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine share acquisitions resulting from dividend re-investment plans for two executives.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share transactions executed on the London Stock Exchange.
Key Facts for Investor Verification
- Executives Involved: Mr. D S Redfern (Chief Strategy Officer) and Mrs. V A Whyte (Company Secretary).
- Transaction Nature: Both transactions were acquisitions of ordinary shares following the re-investment of dividends paid on April 11, 2019.
- Account Type: Shares were held within an Individual Savings Account (ISA).
- Market Data: Transactions occurred on the London Stock Exchange (XLON) at a price of £15.6873 per share.
- Volume: Mr. Redfern acquired 29 shares; Mrs. Whyte acquired 25 shares.